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Although echocardiography has greatly improved the
diagnostic possibilities in equine medicine, determining
the prognosis remains a difficult task. In humans, max-
imal cardiac power output (CPO) has been described
as a powerful indicator of exercise capability and out-
come in heart disease. The aim of the study is to describe
the measurement of CPO by echocardiography and by
thermodilution in healthy horses. Six healthy horses
were studied. Cardiac output (CO) was measured by
thermodilution and Doppler echocardiography at rest
and during a pharmacologic stress test consisting of
35 mg/kg atropine followed by incremental steps 2, 4,
6, and 8 mg/kg/min of dobutamine infusion. Mean
arterial pressure (MAP) was measured invasively by
a catheter introduced into the transverse facial artery.
CPO was calculated as the product of CO and MAP.
Baseline CPO measured by thermodilution and by
Doppler echocardiography was 10.7  3.3 and 13.7 
4.5 watts, respectively. CPO increased significantly
with pharmacologic stimulation and reached maximal
CPO of 66.4  3.6 and 60.4  5.1 watts when mea-
sured by thermodilution and Doppler echocardiogra-
phy, respectively. This study describes an estimation of
CPO in horses. Further studies should demonstrate
the usefulness of CPO as a predictive indicator in horses
suffering from cardiac disease.
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Commonly, when cardiac function is assessed in exercise
physiology or medical research, indexes of either blood
flow (eg, cardiac output) or pressure (eg, pulmonary wedge
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patients.3 Cardiac power output (CPO) as an alternative
measure of cardiac performance has been proposed by
Tan.4 Cardiac power output is the product of cardiac out-
put (CO) and mean systemic arterial pressure (MAP), and
is, from the point of view of fluid dynamics, the most
logical variable to represent cardiac performance. The
heart generates both blood pressure and flow, and there-
fore both components need to be determined if a compre-
hensive measure of overall cardiac function is to be
obtained.4-6 Maximal CPO, achieved either by exercise
or by pharmacologic stimulation, has been described as
a powerful indicator of exercise capability and outcome in
heart disease in humans.7-9 Until now, CPO has not
been measured in horses, although other forms of cardiac
stress testing based on echocardiography after exercise or
during or after pharmacologic stimulation have recently
been described in horses. The use of echocardiography
has revolutionized equine cardiology by providing an
excellent diagnostic and prognostic tool, especially in cases
of advanced heart disease. However, diagnosing subtle or
occult cardiac disease that limits exercise capacity remains
a challenging task for the equine cardiologist. Therefore,
it seems desirable to investigate the equine heart under
conditions that simulate exercise. Stress echocardiography
has been proposed for this purpose; however, its clinical
utility still needs to be proved.
The aim of the current study was (1) to measure resting
and maximal CPO in healthy horses undergoing pharma-
cologic stress testing and (2) to compare CPO measured
by thermodilution and by Doppler echocardiography, to
establish a minimally invasive method of CPO measure-
ment in horses.MATERIALS AND METHODS
Six healthy horses (age 11.5  5.5 years; body weight
421  71 kg [mean  SD]) were studied. All procedures
were approved by the Ethical Committee for Animal Use
of the Faculty of Veterinary Medicine.
Two 8.5-French catheter-introducers (Percutaneous
Sheath Introducer Set, Arrow, Reading, PA) were placed
in the left jugular vein. A 7.5-French-wide and 130-cm-
long thermistor catheter (Swan-Ganz catheter, Baxter,
Lessines, Belgium) was inserted into the pulmonary artery219
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(Tempo5, Cordis, Waterloo, Belgium) was passed into
the right atrium via the upper introducer. A 20-gauge
catheter (Intraflon2, Vygon, Ecouen, France) was placed
into the transverse facial artery and connected via a fluid-
filled pressure transducer to a monitoring system (Series
7010, Marquette Electronics Inc., Milwaukee, WI) to
measure MAP throughout the protocol. Correct place-
ment of all the catheters was confirmed by characteristic
pressure tracings.
Echocardiographic examinations were performed with
a 2.5-MHz phased-array transducer (System Five, GE
Ultrasound, Zaventem, Belgium) and recorded for later
analyses. The left ventricular outflow tract was viewed
from a right parasternal long axis view. The end-diastolic
aortic diameter was measured at the largest perpendicular
diameter of the sinus of valsalva using the leading edge
method. Echocardiographic recordings of a left parasternal
left outflow tract view served for the Doppler measurement
of the aortic flow as previously described.10 The velocity
time integral (VTI) was obtained by tracking the black/
white interface of the pulsed-wave Doppler signal of the
aortic flow.
The echocardiographic recordings of the aortic flow
tracings were performed at rest and 3 minutes after the
onset of each step of the pharmacologic stress test, which
consisted of a single intravenous injection of 35 mg/kg of
atropine (crystalline powder in 1% aqueous solution,
Sigma-Aldrich, Bornem, Belgium) followed by incremen-
tal steps of dobutamine infusion (Dobutrex, Eli Lilly, Brus-
sels, Belgium) at rates of 2, 4, 6, and 8 mg/kg/min (Model
960, Imed Coperation, San Diego, CA). Criteria to inter-
rupt the procedure included excessive restlessness of the
horse, persistent ventricular arrhythmias, or less than 5%
increase of heart rate (HR) in comparison with the preced-
ing step. Simultaneously to the Doppler recordings of
the aortic flow, thermodilution-derived cardiac output
(COTD) was determined by three injections of 35 mL
ice-cold saline solution and automatically computed by
a cardiac output computer (Cardiomax II, Columbus
Instruments, Columbus, OH). Themean of the threemea-
surements was calculated to estimate the cardiac output in
each of the steps of the pharmacologic challenge. Simulta-
neously, an apex-base echocardiogram was recorded for
later calculation of HR.
The mean of three measurements of the aortic diameter
(d) was used to calculate the aortic cross-sectional area
(CSA), assuming a circular and constant orifice, by the fol-
lowing formula: CSA¼ [d/2]2*p. The mean of three VTI
was used to calculate stroke volume (SV) using the follow-
ing formula: CSA* VTI. Doppler-derived cardiac output
(CODO) was calculated as the product of SV and HR. Car-
diac power output was calculated for the two methods of
COmeasurement according to Chantler and co-workers11as follows: CPO¼ (CO*MAP) * k, where k is a conversion
factor (2.22*103) into watts. To compare SV of the two
methods, the thermodilution-derived SV was calculated
by dividing thermodilution-derived CO by the HR.
Eachvariablewas analyzed separatelywith a repeatedmea-
sures model with an auto-regressive variance-covariance
matrix for the repeated measures (Proc mixed, SAS/STAT
software, SAS Institute Inc.,Cary,NC).Least-squaremeans
were computed for each step of the protocol. Differences
were considered significant at P < .05. Comparison
between CPODO and CPOTD was done by Bland-Altman
analysis, which is considered the method of choice for com-
paring two clinical measurement techniques12 (Medcalc
Software, Mariakerke, Belgium).RESULTS
Results of measured (HR, MAP, COTD, SVDO) and calcu-
lated variables (SVTD,CODO,CPOTD,CPODO)before and
during pharmacologic stimulation are given in Table 1.
Bland-Altman analysis (Fig. 1) demonstrated a mean bias
between the twomethods of CPO estimation of 4.19 watts
with a 95% confidence interval for the mean bias 1.79 to
6.85 watts. The limits of agreement were 9.24 watts
and 17.62 watts. The 95% confidence interval for the upper
limit of agreement was 13.49 to 21.75 watts; the 95%
confidence interval for the lower limit of agreement was
13.37 to 5.11 watts.DISCUSSION
All horses tolerated the procedure without incident. In two
horses, the protocol was interrupted after a dobutamine
infusion rate of 6 mg/kg/min, becausemaximal cardiac stim-
ulation had been reached. The pharmacologic stress test of
the current study induced a 4.4- to 6.2-fold increase in
CPO at maximal stimulation, which is comparable to the re-
sults obtained in humans7 and higher than those obtained in
dogs13 and calves.14 The observed increase in CPO was me-
diatedby an increase inMAPandHR,whereas SVslightlyde-
creased with increasing cardiac stimulation. Decreased SV
during pharmacologic stimulation has already been demon-
strated in previous studies in ponies15 and humans16 and is
probably the result of decreased venous return, lowering pre-
load. In contrast, SV ismaintained during exercise because of
themuscular pump function. Therefore, CPO obtained dur-
ing pharmacologic stress test in the current study is probably
lower than the maximal CPO that could be achieved during
maximal exercise. However, maximal CPO for this pharma-
cologic protocol was achieved, because there was no more
significant increase of MAP and HR between the two final
steps of pharmacologic stimulation. Other determinants of
cardiac performance such as contractility and afterload have
not been investigated in detail, but increasing fractional
shortening demonstrated in horses undergoing the same
Table 1. Mean values of heart rate, mean systemic arterial pressure, cardiac output, and cardiac power output measured
by thermodilution and by Doppler echocardiography in six horses undergoing pharmacological stress test
Dose (n[ 6) HR (bpm) MAP (mmHg) CO TD (L/min) CO DO (L/min) CPO TD (W) CPO DO (W)
Baseline (n ¼ 6) 43.4  5.1 135.9  8.7 35.3  5.5 45.3  7.2 10.7  3.3 13.7  4.5
Atropine 35 mg/kg
(n ¼ 6)
69.7  5.2 162.1  8.8 45.7  5.56 64.4  7.3 16.1  3.3 22.3  4.5




98.8  5.1 189.3  8.7 63.4  5.5 82.8  7.2 26.9  3.3 35.2  4.5




123.2  5.1 213.9  8.7 87.6  5.5 101.4  7.2 41.8  3.3 48.3  4.5




140.2  5.1 234.6  8.7 102.1  5.5 116.7  7.2 53.4  3.3 55.1  4.5




146.5  5.5 233.8  10.0 120.2  5.7 119.6  7.6 66.4  3.6 60.4  5.1
0, A, 2, 4 0, A, 2 0, A, 2, 4, 6 0, A, 2, 4 0, A, 2, 4, 6 0, A, 2, 4
All values expressed as least square means  S.E.; p < 0.05. 0¼ significantly different from baseline, A ¼ significantly different from atropine, 2 ¼
significantly different from 2 mg/kg/min of dobutamine infusion, significantly different form 4 mg/kg/min of dobutamine infusion, significantly
different from 6 mg/kg/min of dobutamine infusion. HR¼ heart rate, MAP¼mean systemic arterial pressure, CO¼ cardiac output, CPO¼ cardiac
power output, TD ¼ thermodilution, DO ¼ Doppler echocardiography.
Fig. 1. Bland-Altman plot of cardiac power output (CPO) measurements by thermodilution (TD) and Doppler
echocardiography in six horses during a pharmacological stress test.—meanbias, ---- upper and lower limit of agreement
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creasing contractility.17 Afterload, often estimated by sys-
temic vascular resistance and calculated as MAP divided by
CO, is decreasing during this form of stress test. These data
indicate that pharmacologic stimulation mimics exerciseonly incompletely. However, the success of CPO as an esti-
mate of cardiac performancedependsprimarily on its capacity
to reachmaximal stimulation for a given test.7-9This criterion
seemed to be fulfilled by the given test, because there was no
observable increase in HR, COTD, or MAP in two of the six
222 C Sandersen et al  Vol 29, No 4 (2009)horses at a dobutamine infusion rate of 6 mg/kg/min; in the
remaining fourhorses, no further stimulationwasobserved in
the final two steps of pharmacologic stimulation.
An earlier study by Blissit and co-workers18 has demon-
strated a mean bias of 4.01  12.26 L/min CO measured
by thermodilution and Doppler echocardiography, which
is comparable to the current study. Thermodilution,
although often considered as the gold standard, is subject
to measurement errors caused by preheating of the thermal
indicator, errors in injectate volumes, and injection time.19
The advantage of Doppler echocardiography as a means of
CO estimation is its noninvasiveness. However, during
stress echocardiography, an increased dispersion of the
signal is observed, whichmakes it difficult to identify modal
velocity envelopes accurately.14,18 These findings are also
reflected in the Bland-Altman analysis, which showed
a considerable lack of agreement between the twomethods
and indicated that variation in at least one method depends
on magnitude of measurements. However, both tech-
niques were capable of demonstrating a gradual increase
of CPO with increasing stimulation.
In conclusion, the results of the current study indicate
that CPOmeasurement during pharmacologic stimulation
is feasible in horses and can be performed noninvasively
using Doppler echocardiography. Further studies are
needed to show the usefulness of CPO measurement as
a prognostic indicator of cardiac disease in horses.REFERENCES
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